The
ability of bacteria to evolve in response to pressure from antibiotics has been
recognized since the discovery of penicillin. In less than a century, a complex
array of factors has led to the emergence of bacteria that no longer respond to
any approved antibiotics. Numerous recent calls to action have highlighted the
urgent need to respond to this growing global health threat with improved
surveillance and infection control, more judicious use of antibiotics, new
prevention measures, and new therapeutic strategies to combat resistant
bacteria.
AR
is a complex and multifaceted problem that is driven by many factors,
including:
- Bacterial population density in health care facilities, which allows transfer of bacteria within a community and enables resistance to emerge;
- Inadequate adherence to proven hospital hygiene measures;
- An increasing number of high risk populations, including chemotherapy, dialysis, and transplant patients as well as those in long-term care facilities;
- Overuse of antibiotics in agriculture;
- Global travel and trade, which can lead to transfer of resistant infections and resistance genes;
- Poor sanitation in certain areas, which can contaminate water systems and spread resistant bacteria in sewage;
- Inappropriate use of antibiotics in human medicine (e.g., for viral infections);
- Overprescribing of broad-spectrum drugs, which can exert selective pressure on commensal bacteria and predispose to secondary infection; and
- Lack of rapid diagnostics to help guide appropriate use of antibiotics.
Antimicrobial
resistance has become a global crisis. In the U.S. alone, drug-resistant
infections cause roughly 23,000 deaths a year, and the supply of new
antibiotics has dwindled. In a commentary in JAMA this week, NIAID Director
Anthony S. Fauci, M.D., along with colleague Hilary D. Marston, M.D., M.P.H.,
examine the problem and highlight how NIAID has recently adjusted its
antimicrobial research efforts to apply innovative approaches to basic,
clinical and translational research to address the problem.
Posted by Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources